Somapacitan-beco
Somapacitan-beco
Somapacitan-beco (pronunciation: so-ma-pa-ci-tan-be-co) is a growth hormone analog used in the treatment of growth hormone deficiency in adults. It is a long-acting growth hormone developed by Novo Nordisk.
Etymology
The name "Somapacitan-beco" is derived from "Soma", a term used in biology to refer to the body of an organism, and "pacitan", a term used in pharmacology to refer to a drug that is designed to be released slowly over time. The "-beco" suffix is a proprietary designation used by Novo Nordisk.
Usage
Somapacitan-beco is used to treat adults with growth hormone deficiency. It is administered via subcutaneous injection once a week. The drug works by mimicking the effects of natural growth hormone in the body, helping to regulate body composition, body fluids, muscle and bone growth, sugar and fat metabolism, and possibly heart function.
Related Terms
See Also
External links
- Medical encyclopedia article on Somapacitan-beco
- Wikipedia's article - Somapacitan-beco
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski